This study included 76 newly diagnosed RA patients and 50 matched controls. Basal JAK2 mutation was assessed by PCR in blood samples, TNF-α and IL 6 were measured by ELISA in serum of patients and controls. All patients started therapy with conventional synthetic DMARDs (including methotrexate). Response assessment at 3rd month was evaluated by DAS28 and ACR response criteria. JAK2 mutation was correlated with different clinical and laboratory parameters of patients.
Name: JAK expression
Description: Impact of pretreatment JAK2 mutation on response of Rheumatoid Arthritis patients to first line csDMARDS.
Measure: JAK2 mutation expression in newly diagnosed RA patients Time: 6 monthsAllocation: Non-Randomized
Single Group Assignment
There is one SNP
Impact of pretreatment JAK2 mutation on response of Rheumatoid Arthritis patients to first line csDMARDS.. Inclusion Criteria: - New case RA patients - good liver and renal function Exclusion Criteria: - Other autoimmune diss - Malignancy - Active viral infection - pregnancy and lactation Inclusion Criteria: - New case RA patients - good liver and renal function Exclusion Criteria: - Other autoimmune diss - Malignancy - Active viral infection - pregnancy and lactation Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression Arthritis Arthritis, Rheumatoid PCR detection of the JAK-2 V617F mutation using ASO specific PCR Genetic marker: The detection of jak2 V617F mutation were done by using the following primers (JAK2 Reverse: 5' CTGAATAGTCCTACAGTGTTTTCAGTTTCA 3', JAK2 Forward (specific): 5' AGCATTTGGTTTTAAATTATGGAGTATATT 3' and JAK2 Forward (internal control): 5' ATCTATAGTCATGCTGAAAGTAGGAGAAAG 3'). --- V617F ---
Impact of pretreatment JAK2 mutation on response of Rheumatoid Arthritis patients to first line csDMARDS.. Inclusion Criteria: - New case RA patients - good liver and renal function Exclusion Criteria: - Other autoimmune diss - Malignancy - Active viral infection - pregnancy and lactation Inclusion Criteria: - New case RA patients - good liver and renal function Exclusion Criteria: - Other autoimmune diss - Malignancy - Active viral infection - pregnancy and lactation Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression Arthritis Arthritis, Rheumatoid PCR detection of the JAK-2 V617F mutation using ASO specific PCR Genetic marker: The detection of jak2 V617F mutation were done by using the following primers (JAK2 Reverse: 5' CTGAATAGTCCTACAGTGTTTTCAGTTTCA 3', JAK2 Forward (specific): 5' AGCATTTGGTTTTAAATTATGGAGTATATT 3' and JAK2 Forward (internal control): 5' ATCTATAGTCATGCTGAAAGTAGGAGAAAG 3'). --- V617F --- --- V617F ---